| 06/08/26 | 13:00:21 | 6 Aug 2026 | | Holding(s) in Company |
| 31/07/26 | 17:32:40 | 31 Jul 2026 | | Holding(s) in Company |
| 31/07/26 | 07:00:06 | 31 Jul 2026 | | Extension of Option Exercise Period |
| 28/07/26 | 15:40:16 | 28 Jul 2026 | | Holding(s) in Company |
| 27/07/26 | 07:00:09 | 27 Jul 2026 | | Result of Retail Offer and Total Voting Rights |
| 24/07/26 | 07:30:00 | 24 Jul 2026 | | Correction: Merger and Financing |
| 23/07/26 | 16:30:21 | 23 Jul 2026 | | Oversubscribed UK Placing |
| 23/07/26 | 08:05:45 | 23 Jul 2026 | | Merger and Financing |
| 23/07/26 | 08:04:46 | 23 Jul 2026 | | Launch of Retail Offer |
| 23/07/26 | 08:04:39 | 23 Jul 2026 | | Proposed UK Placing |
| 26/06/26 | 14:13:45 | 26 Jun 2026 | | Scancell: Response to Press Speculation |
| 28/04/26 | 07:00:11 | 28 Apr 2026 | | FDA Fast Track Designation for iSCIB1+ |
| 02/04/26 | 07:00:05 | 2 Apr 2026 | | Scancell announces CFO transition |
| 29/01/26 | 07:00:07 | 29 Jan 2026 | | Half-year Financial Report |
| 26/01/26 | 07:00:02 | 26 Jan 2026 | | FDA clearance of IND application for iSCIB1+ |
| 22/01/26 | 07:00:08 | 22 Jan 2026 | | Notice of Results |
| 09/12/25 | 07:00:05 | 9 Dec 2025 | | Continued improvement in PFS with iSCIB1+ |
| 07/11/25 | 07:00:04 | 7 Nov 2025 | | Research Update |
| 30/10/25 | 15:30:05 | 30 Oct 2025 | | Result of AGM |
| 03/10/25 | 07:00:13 | 3 Oct 2025 | | Notice of AGM |
| 16/09/25 | 07:00:14 | 16 Sept 2025 | | Director Dealing |
| 11/09/25 | 07:00:12 | 11 Sept 2025 | | Final Results |
| 04/09/25 | 07:00:18 | 4 Sept 2025 | | Notice of Results |
| 08/08/25 | 12:31:39 | 8 Aug 2025 | | Director Dealing |
| 04/08/25 | 10:23:05 | 4 Aug 2025 | | Director/PDMR Shareholding |
| 22/07/25 | 07:00:06 | 22 Jul 2025 | | Strong Phase 2 data on iSCIB1+ in Melanoma |
| 16/07/25 | 07:00:02 | 16 Jul 2025 | | Share Option Exercise |
| 25/06/25 | 07:00:06 | 25 Jun 2025 | | Scancell initiates new arm in SCOPE Phase 2 study |
| 21/05/25 | 07:00:10 | 21 May 2025 | | Director Dealing |
| 14/04/25 | 07:00:08 | 14 Apr 2025 | | Partnership with NHS Cancer Vaccine Launch Pad |
| 01/04/25 | 07:00:12 | 1 Apr 2025 | | Scancell to present at 2025 AACR Annual Meeting |
| 20/02/25 | 07:00:09 | 20 Feb 2025 | | Issue of share options |
| 17/02/25 | 07:00:05 | 17 Feb 2025 | | Scancell presenting at AACR IO conference |
| 30/01/25 | 07:00:06 | 30 Jan 2025 | | Interim Results |
| 23/01/25 | 07:00:09 | 23 Jan 2025 | | Notice of Interim Results |
| 09/01/25 | 07:00:04 | 9 Jan 2025 | | Modi-1 Vaccine Achieves Early Clinical Validation |
| 09/12/24 | 11:41:51 | 9 Dec 2024 | | Result of Retail Offer and Total Voting Rights |
| 05/12/24 | 12:39:40 | 5 Dec 2024 | | Result of Placing and Subscription |
| 04/12/24 | 18:03:05 | 4 Dec 2024 | | Retail Offer for up to £1 million |
| 04/12/24 | 17:59:08 | 4 Dec 2024 | | Proposed fundraise in excess of £8.5 million |
| 04/12/24 | 07:00:06 | 4 Dec 2024 | | Second Commercial License Agreement with Genmab |
| 18/11/24 | 07:00:04 | 18 Nov 2024 | | Positive data from Phase 2 SCOPE trial with SCIB1 |
| 25/10/24 | 15:26:51 | 25 Oct 2024 | | Result of Annual General Meeting |
| 24/10/24 | 07:00:09 | 24 Oct 2024 | | Holding(s) in Company |
| 22/10/24 | 07:00:06 | 22 Oct 2024 | | Scancell Appoints Dr Phil L’Huillier as CEO |
| 01/10/24 | 07:00:12 | 1 Oct 2024 | | Notice of AGM |
| 24/09/24 | 07:00:10 | 24 Sept 2024 | | Results Year Ended 30 April 2024 |
| 18/09/24 | 07:00:10 | 18 Sept 2024 | | Notice of Final Results |
| 17/09/24 | 07:00:08 | 17 Sept 2024 | | Strategic Partnership with PharmaJet |
| 02/09/24 | 07:00:09 | 2 Sept 2024 | | Scancell to attend upcoming conferences |
